-+ 0.00%
-+ 0.00%
-+ 0.00%
Kalaris Therapeutics to present Phase 1a TH103 data at Clinical Trials at the Summit 2026
Share
Listen to the news
Kalaris Therapeutics to present Phase 1a TH103 data at Clinical Trials at the Summit 2026
  • Kalaris Therapeutics will present Phase 1a single-ascending-dose data for TH103 at Clinical Trials at the Summit 2026 on June 13, 2026.
  • Readout covers treatment-naïve patients with neovascular age-related macular degeneration, a key indication for the company’s lead retinal program.
  • Presentation is scheduled for 7:09 a.m. PDT in Las Vegas, within a session focused on novel mechanisms of action.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending